Press Releases

Month Year

Email Alerts

Feb 20, 2020

Biostage Submitted Official Response to FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it has submitted its official response to...
Jan 2, 2020

Biostage Provides Update on FDA Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, received the anticipated formal response from the U.S. Food and...
Dec 3, 2019

Biostage Receives Response from the FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant

Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it was notified via email on November 27,...
Nov 12, 2019

Biostage Reports Third Quarter 2019 Financial Results

Biostage, Inc. (OTCQB: BSTG), a bioengineering company developing next-generation esophageal implants, today announced its financial results for the three and nine months ended September 30, 2019....
Nov 6, 2019

Biostage to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Business Update

- Conference Call with Live Audio Webcast on Tuesday November 12th at 9:00 AM ET -

Biostage, Inc. (OTCQB: BSTG), a bioengineering company developing next-generation esophageal implants, announced today that it will report its financial results for the three and nine months ended...

Show per page